We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Ox7.0
Oxiracetam Research
Likely helpsHigh safety
11 peer-reviewed studies
What the evidence says
Likely helps
Oxiracetam appears to help in 4 of 4 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2010–2026 with a typical study size of 1,856 participants.
Based on 11 studies · 4 meta-analyses · 5 RCTs · 49,934 total participants
Confidence
High
What the studies found
4helped· 7 more without graded effect data
By outcome
Cognitive functionEnhances memory and learning via glutamatergic modulation · 2-4 weeks
Likely helps9 studies
Neuroprotection & brain aging
Mostly mechanism / observational3 studies
Heart & blood pressure
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Therapeutic & clinical
Too few graded studies2 studies
Recovery
Too few graded studies1 study
By the numbers
Pulled from 9 studies with measurable effects
Likely real effects
100%
across studies
People studied
50k
typical study: 1856 people
Strongest designs
9
4 pooled, 5 randomised
Showed benefit
100%
4/4 studies
Populations Studied
Post-stroke patients1
Dementia patients1
Vascular dementia patients1
Patients with vascular cognitive dysfunction1
Active research area
7 studies in the last 5 years · Latest meta-analysis: 2021
201020182026
1Cognitive function improvement post-strokeMeta-AnalysisCited 34×n=2,104 · very large study2021
Oxiracetam demonstrated significant cognitive benefits in post-stroke patients with improved MMSE and ADL scores.
Chen X, Wang L, Deng Y, Li X, He Q · Neurological Sciences (2021)
Statistically significant improvement in cognitive function post-stroke
Improved activities of daily living compared to standard care
Low incidence of adverse effects across pooled trials
In this review, effect of hot environment on CHI-induced brain pathology is discussed.
In addition, whether nanodelivery of oxiracetam together with neprilysin and monoclonal antibodies (mAb) to amyloid beta peptide and p-tau could lead to superior neuroprotection in CHI is explored.
Our results show that co-administration of oxiracetam with neprilysin and mAb to AβP and p-tau significantly induced superior neuroprotection following CHI in hot environment, not reported earlier.
5Mental status and cognitive function improvementMeta-AnalysisCited 2×2020
Based on the current clinical evidence, olacetam is more effective and safer than alternatives in the treatment of vascular cognitive dysfunction.
Yi Z et al. · Journal of nanoscience and nanotechnology (2020)
Noticeable benefit
← WorseNo effectBetter →
Likely real
The results of the meta-analysis showed that compared with placebo and other medications, oxiracetam significantly improved the mental status of patients, Concise Mental State Checklist score [mean difference (MD)= 5.29, P < 0.01] and Montreal Cognitive Assessment score (MD = 4.32, P < 0.01).
The Barthel Index demonstrated that oxiracetam significantly improved the quality of the daily life of patients (MD = 18, P < 0.01), but there was no difference between olacetam and placebo or other medications in the rating of activities of daily living (ADLs).
The total effective rate of olacetam was significantly higher than that of other treatments (P < 0.01).
7Efficacy and safety of oxiracetam in vascular cognitive impairmentRCTCited 9×n=500 · large study2023
This trial is meaningful not only to prove the efficacy of oxiracetam, but also evaluate whether exercise can modify the effects of medication and how cognitive function can be restored.
Lim JS et al. · Contemporary clinical trials (2023)
This trial is meaningful not only to prove the efficacy of oxiracetam, but also evaluate whether exercise can modify the effects of medication and how cognitive function can be restored.
Based on calculations of the efficacy rates, our assessments indicate notable improvements in clinical outcomes with some of these agents.
Malykh AG et al. · Drugs (2010)
Differential effects on subtypes of glutamate receptors, but not the GABAergic actions, have been implicated.
Piracetam seems to activate calcium influx into neuronal cells; however, this function is questionable in the light of findings that a persistent calcium inflow may have deleterious impact on neuronal cells.
Although subgroup 2 compounds act via binding to another neuronal receptor (synaptic vesicle 2A), some of the subgroup 3 compounds, such as nefiracetam, are similar to those of subgroup 1.
9Cognitive function improvement in traumatic brain injuryRCT2025
This rct examined the effects of Oxiracetam.
Liu T et al. · Signal transduction and targeted therapy (2025)
Noticeable benefit
← WorseNo effectBetter →
Likely real
The LS mean difference of the L-oxiracetam was significantly higher than the placebo group (8.97, 95% CI 5.69,12.26; P < 0.001; Cohen's d = 0.48 [95% CI: 0.26,0.69]) and the oxiracetam group (4.54, 95% CI 1.85,7.23).
No significant safety concerns were reported.
Despite limitations such as loss to follow-up, the findings of this study provide important evidence for the clinical management of cognitive dysfunction following TBI.
(S)-oxiracetam was safe and tolerated with favorable pharmacokinetic profiles at all study doses, providing dosing evidence for further efficacy evaluation.
Zhang T et al. · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2024)
In the SAD study, no chiral transformation was observed. 55.03% and 36.16% of (S)-oxiracetam was excreted unchanged in urine and feces, respectively.
(S)-oxiracetam was safe and tolerated with favorable pharmacokinetic profiles at all study doses, providing dosing evidence for further efficacy evaluation.
11Treatment effectiveness for vascular cognitive impairmentRCTCited 9×n=120 · medium study2023
The clinical effect is definite.
Wang B et al. · Pakistan journal of pharmaceutical sciences (2023)
Huge benefit
← WorseNo effectBetter →
The combined group had the highest effective rate and the total effective rate was 93.3%.
The combined use of nicergoline and oxiracetam can significantly improve the severity of symptoms and quality of life in patients with vascular cognitive impairment after stroke.
Conclusion: Nicergoline and oxiracetam are effective drugs in the treatment of vascular cognitive impairment (VCI).